Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM65MUI)

Drug Name
AZD1175 Drug Info
Indication
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Discontinued in Phase 1 [1]
Hypertension BA00-BA04 Discontinued in Phase 1 [1]
Obesity 5B81 Discontinued in Phase 1 [1]
Cross-matching ID
PubChem CID
11250433
CAS Number
CAS 863639-43-4
TTD Drug ID
DM65MUI

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cannabinoid receptor 1 (CB1) TT6OEDT CNR1_HUMAN Antagonist [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Cannabinoid receptor 1 (CB1) DTT CNR1 2.907 4.667 2.982 3.678
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Diabetic complication
ICD Disease Classification 5A2Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Cannabinoid receptor 1 (CB1) DTT CNR1 5.59E-02 -0.22 -0.45
Cannabinoid receptor 1 (CB1) DTT CNR1 7.68E-01 -0.06 -0.46
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024090)
2 Clinical pipeline report, company report or official report of AstraZeneca (2009).